Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy

Jing Sun¹, Shaohua He², Peinan Lin¹, Ping Li¹, Xiaomin Cai¹, Lele Li¹, Jing Qian¹, Chong Liu³, Xiao Li³, Yiqian Liu¹, Oluf Dimitri Røe^4,5, Yongqian Shu¹, Xiaofeng Chen^1* and Yanhong Gu¹

¹Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300, Nanjing 210029, PR China

²Department of Oncology, Tumor Hospital of Huaihua, Lulin Road, Huaihua 418000, PR China

³Department of Pathology, the First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300, Nanjing 210029, PR China

⁴Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

⁵Cancer Clinic, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway